ArticleClinical epidemiology2026
Global, Regional, and National Burden of Chronic Myeloid Leukemia Among the Elderly from 1990 to 2021: A Population-Based Epidemiological Analysis.
Article in Clinical epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Molecular Response to Treatment of Chronic Myeloid Leukemia at University Teaching Hospital of Kigali, Rwanda: One-Arm Open Label Prospective Observational Study.Cancer management and research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to evaluate the global, regional, and national burden of chronic myeloid leukemia (CML) in the elderly population from 1990 to 2021, analyzing trends in prevalence, mortality, disability-adjusted life years (DALYs), associated risk factors, and disparities across sociodemographic strata. Methods: Based on data from the Global Burden of Disease (GBD) 2021 study, we analyzed age-standardized rates for CML in adults aged ≥65 years across 204 countries and territories. Trends were quantified using the average annual percentage change (AAPC), and burden estimates were stratified by age, sex, region, and sociodemographic index (SDI). Results: From 1990 to 2021, the global age-standardized prevalence of CML among the elderly declined from 5.80 to 3.37 per 100,000 population (AAPC: -1.71%). Age-standardized mortality decreased from 4.22 to 1.78 per 100,000 (AAPC: -2.73%), and DALYs fell from 68.05 to 27.57 per 100,000 (AAPC: -2.86%). Declines in DALYs were most pronounced in the 65-69 years subgroup (-3.33% per year). Mortality reductions were greater in high-SDI countries (-3.67% per year) than in low-middle-SDI countries (-0.66% per year). In 2021, the highest prevalence was observed in High-income North America and Western Europe, while the highest DALY rates were identified in Oceania, the Caribbean, North Africa, and the Middle East. Smoking remained the leading modifiable risk factor, contributing to 3.93 DALYs per 100,000 in 2021. Conclusion: Over the past three decades, significant improvements in survival and reductions in disease burden have been achieved for elderly CML patients globally, attributable to therapeutic advances. However, substantial disparities persist across sexes and SDI levels. These findings highlight the need for targeted health strategies, equitable access to care, and age-specific guidelines to address the growing burden of CML in aging populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.